Novel oral anticoagulants to prevent stroke in atrial fibrillation

Nature Reviews Cardiology

Volumn 7, Issue 3, 2010, Pages 149-154

  Verheugt, Freek W A ^a  

^a Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; APIXABAN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; COUMARIN DERIVATIVE; DABIGATRAN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; OTAMIXABAN; PLACEBO; RIVAROXABAN; WARFARIN; XIMELAGATRAN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTERY EMBOLISM; BLEEDING; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART REINFARCTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER TOXICITY; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG EMBOLISM; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD COAGULATION; DRUGS, INVESTIGATIONAL; FACTOR XA; HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; RISK FACTORS; STROKE; THROMBIN; TREATMENT OUTCOME; WARFARIN;

EID: 77649096829     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2009.235     Document Type: Review

References (38)

1. Wolf, P. A., Abbott, R. D. &Kannel, W. B. Atrial fibrillation: a major contributor to stroke. The Framingham study. Arch. Intern. Med. 147, 1561-1564 (1987).
2. Kopecky, S. L. et al. The natural history of lone atrial fibrillation. A population-based study over three decades. N. Engl. J. Med. 317, 669-674 (1987).
3. Brouwer, M. A. &Verheugt, F. W. Oral anticoagulants in acute coronary syndromes. Circulation 105, 1270-1274 (2002).
4. Lip, G. Y., Hart, R. G. &Conway, D. S. Antithrombotic therapy for atrial fibrillation. BMJ 325, 1022-1025 (2002).
5. Olsen, S. B. for the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362, 1691-1698 (2003).
6. Gage, B. F. et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285, 2864-2870 (2001).
7. De Caterina, R. et al. Anticoagulants in heart disease: current status and perspectives. Eur. Heart J. 28, 880-913 (2007).
8. Azar, J. A. et al. Optimal intensity of oral anticoagulant therapy after myocardial infarction. J. Am. Coll. Cardiol. 27, 1349-1355 (1996).
9. Hurlen, M., Abdelnoor, M., Smith, P., Erikssen, J. &Arnesen, H. Warfarin, aspirin, or both after myocardial infarction. N. Engl. J. Med. 347, 969-974 (2002).
10. Eikelboom, J. W. et al. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a metaanalysis. Lancet 355, 1936-1942 (2000).
11. Sabatine, M. S. et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, activecontrolled, phase 2 trial. Lancet 374, 787-795 (2009).
12. Van Es, R. F., Jonker, J. J., Verheugt, F. W., Deckers, J. W. &Grobbee, D. E. for the Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2 (ASPECT-2) Research Group. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 360, 109-113 (2002).
13. Hylek, E. M. et al. Effect of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N. Engl. J. Med. 349, 1019-1026 (2003).
14. Wysowski, D. K., Nourjah, P. &Swartz, L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch. Intern. Med. 167, 1414-1419 (2007).
15. Hayden, M., Pignone, M., Phillips, C. &Mulrow, C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the, U. S. Preventive Services Task Force. Ann. Intern. Med. 136, 161-172 (2002). (Pubitemid 34073943)
16. Yusuf, S. et al. for the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345, 494-502 (2001).
17. Bhatt, D. L. et al. for the Charisma Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med. 354, 1706-1717 (2006).
18. Connolly, S. et al. for the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367, 1903-1912 (2006).
19. Verheugt, F. W. Good old warfarin for stroke prevention in atrial fibrillation. Lancet 367, 1877-1878 (2006).
20. Connolly, S. J. et al. for the ACTIVE Investigators. Effect of clopidogrel added to aspirin in atrial fibrillation. N. Engl. J. Med. 360, 2066-2078 (2009).
21. Hellemons, B. S. et al. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ 319, 958-964 (1999).
22. Garcia, D. &Hylek, E. Stroke prevention in elderly patients with atrial fibrillation. Lancet 370, 460-461 (2007).
23. Mant, J. et al. for the BAFTA Investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 370, 493-503 (2007). (Pubitemid 47212371)
24. Ansell, J. et al. Pharmacology and management of the vitamin K antagonists. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133, 160S-198S (2008). (Pubitemid 351892967)
25. Fiessinger, J. N. et al. for the THRIVE Treatment Study Investigators. Ximelagatran vs lowmolecular weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 293, 681-689 (2005).
26. Shulman, S., Wahlander, K., Lundstrom, T., Billing Clason, S. &Eriksson, H. for the THRIVE III Investigators. Secondary prevention of venous thromboembolism with the direct thrombin inhibitor ximelagatran. N. Engl. J. Med. 349, 1713-1721 (2003).
27. Wallentin, L. et al. for the ESTEEM Investigators. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 362, 789-797 (2003).
28. Albers, G. W. et al. and the SPORTIF Executive Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 293, 690-698 (2005).
29. Connolly, S. J. et al. for the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361, 1139-1151 (2009).
30. Agnelli, G. et al. for the ODIXa-DVT Investigators. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation 116, 180-187 (2007).
31. Eriksson, B. I. et al. for the RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N. Engl. J. Med. 358, 2765-2775 (2008).
32. Kakkar, A. K. et al. for the RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial. Lancet 372, 31-129 (2008).
33. Lassen, M. R. et al. for the RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N. Engl. J. Med. 358, 2776-2786 (2008).
34. Turpie, A. G. et al. for the RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4). Lancet 373, 1673-1680 (2009).
35. Hylek, E. M., Frison, L., Henault, L. E. &Cupples, A. Disparate stroke rates on warfarin among contemporaneous cohorts with atrial fibrillation: potential insights into risk from a comparative analysis of SPORTIF-III versus SPORTIF.-V. Stroke 39, 3009-3014 (2008).
36. Ezekowitz, M. D. et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am. J. Cardiol. 100, 1419-1426 (2007).
37. Mega, J. et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 374, 29-38 (2009).
38. Alexander, J. H. for the APPRAISE Steering Committee and Investigators. Apixaban, an oral direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Ischemic and Safety events (APPRAISE) Trial. Circulation 119, 2877-2885 (2009).